+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients A 3-Year Follow-Up



Lipoprotein-Associated Phospholipase A2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients A 3-Year Follow-Up







The aim of this study was to examine the prognostic value of lipoprotein-associated phospholipase A2 (Lp-PLA2) associated with high-density lipoprotein (HDL) (HDL-Lp-PLA2) in patients with stable coronary artery disease (CAD). Lp-PLA2 is a novel risk factor for cardiovascular disease. It has been postulated that the role of Lp-PLA2 in atherosclerosis may depend on the type of lipoprotein with which it is associated. Total plasma Lp-PLA2 and HDL-Lp-PLA2 mass and activity, lipids, and C-reactive protein were measured in 524 consecutive patients with stable CAD who were followed for a median of 34 months. The primary endpoint was cardiac death, and the secondary endpoint was hospitalization for acute coronary syndromes, myocardial revascularization, arrhythmic event, or stroke. Follow-up data were obtained from 477 patients. One hundred twenty-three patients (25.8%) presented with cardiovascular events (24 cardiac deaths, 47 acute coronary syndromes, 28 revascularizations, 22 arrhythmic events, and 2 strokes). Total plasma Lp-PLA2 mass and activity were predictors of cardiac death (hazard ratio [HR]: 1.013; 95% confidence interval [CI]: 1.005 to 1.021; p = 0.002; and HR: 1.040; 95% CI: 1.005 to 1.076; p = 0.025, respectively) after adjustment for traditional risk factors for CAD. In contrast, HDL-Lp-PLA2 mass and activity were associated with lower risk for cardiac death (HR: 0.972; 95% CI: 0.952 to 0.993; p = 0.010; and HR: 0.689; 95% CI: 0.496 to 0.957; p = 0.026, respectively) after adjustment for traditional risk factors for CAD. Total plasma Lp-PLA2 is a predictor of cardiac death, while HDL-Lp-PLA2 is associated with lower risk for cardiac death in patients with stable CAD, independently of other traditional cardiovascular risk factors.

Accession: 036643240

Download citation: RISBibTeXText


Related references

Lipoprotein-Associated Phospholipase A 2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients A 3-Year Follow-Up. 2012

Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. Journal of the American College of Cardiology 60(20): 2053-2060, 2012

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart and Vessels 29(1): 35-41, 2014

Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opinion on PharmacoTherapy 12(10): 1481-1489, 2011

Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. Journal of the American College of Cardiology 54(14): 1238-1245, 2009

Cardiac risk factors in descendants of parents with history of coronary artery disease (CAD): an evaluation focusing on small dense low density lipoprotein cholesterol (sdLDLc) and high density lipoprotein cholesterol (HDLc). Indian Journal of Biochemistry and Biophysics 50(5): 453-461, 2013

Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients. Metabolic Syndrome and Related Disorders 8(6): 515-522, 2010

Cholesterol esterification rates in very low density lipoprotein and low density lipoprotein depleted plasma relation to high density lipoprotein subspecies sex hyperlipidemia and coronary artery disease. Arteriosclerosis and Thrombosis 11(1): 64-70, 1991

High density lipoprotein and metabolic risk factors of ischemic heart disease in men aged up to 50 years part i. high density lipoprotein cholesterol high density lipoprotein triglycerides high density lipoprotein phospholipids and phospholipid fractions in dyslipidemias. Zywienie Czlowieka I Metabolizm 13(1): 26-37, 1986

Lipid: Protein Ratios in High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL) in Patients with Angiographically Defined Coronary Artery Disease (CAD). Clinical Science 77(S21): 21p.3-21p, 1989

Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127(8): 891-904, 2013

High density lipoprotein and coronary artery disease risk factors in children with different lipoprotein profiles: Bogalusa Heart Study. Journal of Chronic Diseases 38(4): 327-338, 1985

High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis 263: 104-111, 2017

Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. European Journal of Clinical Investigation 49(2): E13053, 2019

Lower high-density lipoprotein cholesterol is a significant and independent risk for coronary artery disease in Japanese men. Journal of Atherosclerosis and Thrombosis 16(6): 792-798, 2009